Brad Rodrigue, MD
Internal Medicine · Baton Rouge, LANPI 1497946750
Payments from drug & device makers
Across 508 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$872
- Novo Nordisk$856
- Abbott$666
- AstraZeneca$655
- plus $4K from 29 others
What the payments were for
- Food & beverage$9,295100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $1,149 |
| Lilly USA, LLC | 64 | $1,116 |
| Boehringer Ingelheim | 50 | $872 |
| Novo Nordisk | 53 | $856 |
| Abbott | 31 | $666 |
| AstraZeneca(2 entities) | 28 | $655 |
| Bayer | 24 | $539 |
| Pfizer | 27 | $503 |
| Sumitomo Pharma America, Inc. | 32 | $487 |
| Novartis | 23 | $362 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $257 |
| Merck | 16 | $231 |
| Amgen | 18 | $193 |
| Xeris Pharmaceuticals, Inc. | 7 | $159 |
| Phathom Pharmaceuticals, Inc. | 11 | $149 |
| Idorsia Pharmaceuticals US Inc | 10 | $149 |
| Dexcom, Inc. | 6 | $138 |
| Otsuka America Pharmaceutical, Inc. | 6 | $105 |
| La Jolla Pharmaceutical Company | 1 | $97 |
| Exact Sciences | 6 | $90 |
| AbbVie | 4 | $81 |
| Astellas Pharma US Inc | 4 | $79 |
| Johnson & Johnson | 4 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Sanofi Pasteur Inc. | 3 | $51 |
| Acadia Pharmaceuticals Inc | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,295 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 109 | $115,872 |
| MounjaroTirzepatide | 64 | $81,488 |
| EliquisApixaban | 95 | $64,798 |
| OzempicSemaglutide | 48 | $54,989 |
| FarxigaDapagliflozin Propanediol | 39 | $35,278 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $35,190 |
| LinzessLinaclotide | 41 | $26,615 |
| KerendiaFinerenone | 21 | $24,772 |
| Repatha SureclickEvolocumab | 27 | $16,698 |
| BelsomraSuvorexant | 38 | $16,513 |
| GemtesaVibegron | 29 | $15,023 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $13,469 |
| EntrestoSacubitril/Valsartan | 15 | $11,564 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $6,716 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,954 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $872 | $121,825120 claims |
| Lilly USA, LLCMounjaro | $1,116 | $81,48864 claims |
| PfizerEliquis | $503 | $64,79895 claims |
| Novo NordiskOzempic | $856 | $54,98948 claims |
| AstraZenecaFarxiga | $655 | $35,27839 claims |
| GSKTrelegy Ellipta | $1,149 | $35,19050 claims |
| AbbVieLinzess | $81 | $26,61541 claims |
| BayerKerendia | $539 | $24,77221 claims |
| MerckBelsomra | $231 | $16,51338 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $487 | $15,02329 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $52 | $13,46922 claims |
| NovartisEntresto | $362 | $11,56415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Baton Rouge
- Katherine PearceBaton Rouge$12M
- Donna RyanBaton Rouge$991K
- Gertrude Chimeka AnyanwokeBaton Rouge$611K
- Deepesh PatelBaton Rouge$304K
- John SchwabBaton Rouge$122K
- Barret MurphyBaton Rouge$43K
- Brian GremillionBaton Rouge$27K
- Raoul ManalacBaton Rouge$27K
- Bradley MeekBaton Rouge$20K
- William SmithNew Orleans$50.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.